First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

Breast Cancer Research

Volumn 5, Issue 5, 2003, Pages

  Rivera, Edgardo ^a   Haim Erder, M ^b   Fridman, Moshe ^c   Frye, Debra ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b AMGEN INC   (United States)

^c AMF Consulting Inc   (United States)

Author keywords

chemotherapy; filgrastim; hospitalization; myelosuppression; neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CANCER STAGING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; METHODOLOGY; MIDDLE AGED; NEUTROPENIA; NEUTROPHIL; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; STATISTICS; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; HUMANS; LEUKOCYTE COUNT; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; NEUTROPHILS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0141797711     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr618     Document Type: Article

References (14)

1. J.H. Silber M. Fridman R.S. DiPaola M.H. Erder M.V. Pauly K.R. Fox First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy J Clin Oncol 1998 16 2392 2400 1:STN:280:DyaK1czivFygsg%3D%3D 9667256
2. P. Savvides N. Terrin J. Erban H.R. Selker Development and validation of a patient-specific predictive instrument for the need for dose-reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors Proc ASCO 2001 20 244a
3. J. Crawford H. Ozer R. Stoller D. Johnson G. Lyman I. Tabbara M. Kris J. Grous V. Picozzi G. Rausch R. Smith W. Gradishar A. Yahanda M. Vincent M. Stewart J. Glaspy Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 1991 325 164 170 1:STN:280:DyaK3M3ntVehuw%3D%3D 10.1056/NEJM199107183250305 1711156
4. H. de Graaf P.H. Willemse S.B. Bong H. Piersma T. Tjabbes H. van Veelen J.L. Coenen E.G. deVries Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor pre-menopausal patients with node-positive breast cancer Oncology 1996 53 289 294 1:STN:280:DyaK283psFGquw%3D%3D 10.1159/000227575 8692532
5. V. Trillet-Lenoir J. Green C. Manegold J. Von Pawel U. Gatzemeier B. Lebeau A. Depierre P. Johnson G. Decoster D. Tomita C. Ewen Recombinant granulocyte colony-stimulating factor reduces the infection complications of cytotoxic chemotherapy Eur J Cancer 1993 29A 319 324 1:STN:280:DyaK2c%2FgtFSnsw%3D%3D 10.1016/0959-8049(93)90376-Q 7691119
6. B.K. Link G.T. Budd S. Scott E. Dickman D. Paul G. Lawless M.W. Lee M. Fridman J. Ford W.B. Carter Oncology Practice Pattern Study Working Group Delivering adjuvant chemotherapy to women with early-stage breast cancer: current patterns of care Cancer 2001 92 1354 1367 1:CAS:528:DC%2BD3MXnvVyhu7s%3D 10.1002/1097-0142(20010915)92:6<1354::AID-CNCR1458>3.0.CO;2-P 11745211
7. G.A. Smith M.J. Fine L.L. Lenert R.C. Newbold Project ChemoIn-sight reveals physician practice patterns for adjuvant breast cancer chemotherapy, and compares the dose intensity of CMF, AC, and CAF Proc ASCO 1999 18 78a
8. R. Weiss P. Valagussa A. Moliterni M. Zambetti R. Buzzoni G. Bonadonna Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy. Analysis of drug dosing and toxicity Am J Med 1987 83 455 463 1:STN:280:DyaL1c%2FitFSltg%3D%3D 10.1016/0002-9343(87)90755-8 3116847
9. D.R. Budman D.A. Berry C.T. Cirrincione I.C. Henderson W.C. Wood R.B. Weiss C.R. Ferree H.B. Mus M.R. Green L. Norton E. Frei Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 1998 90 1205 1211 1:CAS:528:DyaK1cXlslylt7w%3D 10.1093/jnci/90.16.1205 9719081
10. G. Bonadonna P. Valagussa A. Moliterni M. Zambetti C. Brambilla Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 1995 332 901 906 1:STN:280:DyaK2M7otlSqsg%3D%3D 10.1056/NEJM199504063321401 7877646
11. J.H. Silber M. Fridman A. Shpilsky O. Even-Shoshan D.S. Smink J. Jayaraman K.R. Fox M.V. Pauly Modeling the cost effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer J Clin Oncol 1998 16 2435 2444 1:CAS:528:DyaK1cXks1Gntbg%3D 9667261
12. B. Rosner Fundamentals of Biostatistics 2000 5 Boston PWS-Kent Publishing Company 63 65
13. D.W. Hosmer S. Lemeshow Applied Logistic Regression 1989 New York John Wiley & Sons 271 274
14. E. Rivera Targeted filgrastim support in patients with early-stage breast carcinoma Cancer 2003